Wall Street Zen upgraded shares of Royalty Pharma (NASDAQ:RPRX – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.
Several other brokerages also recently commented on RPRX. Citigroup boosted their price objective on shares of Royalty Pharma from $70.00 to $78.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Morgan Stanley upped their target price on Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Zacks Research raised Royalty Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 11th. The Goldman Sachs Group reiterated a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Finally, TD Cowen lifted their price target on Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and a consensus price target of $63.29.
View Our Latest Stock Analysis on RPRX
Royalty Pharma Price Performance
Shares of NASDAQ:RPRX opened at $68.53 on Friday. The firm has a 50 day moving average of $61.61 and a 200-day moving average of $54.67. Royalty Pharma has a 12 month low of $37.31 and a 12 month high of $70.37. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $39.40 billion, a PE ratio of 57.11, a PEG ratio of 1.37 and a beta of 0.37.
Royalty Pharma Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, November 13th. Royalty Pharma’s dividend payout ratio is currently 78.33%.
Insider Buying and Selling
In other Royalty Pharma news, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the transaction, the executive vice president owned 270,401 shares of the company’s stock, valued at $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 108,252 shares of company stock valued at $6,327,407. 18.84% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Royalty Pharma
Hedge funds and other institutional investors have recently bought and sold shares of the company. Keel Point LLC bought a new stake in shares of Royalty Pharma during the third quarter worth about $289,000. Waterloo Capital L.P. acquired a new position in shares of Royalty Pharma in the third quarter valued at approximately $229,000. Modern Wealth Management LLC raised its holdings in Royalty Pharma by 16.2% in the 3rd quarter. Modern Wealth Management LLC now owns 4,935 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 689 shares during the last quarter. Utah Retirement Systems raised its holdings in Royalty Pharma by 0.3% in the 3rd quarter. Utah Retirement Systems now owns 63,012 shares of the biopharmaceutical company’s stock valued at $3,677,000 after buying an additional 200 shares during the last quarter. Finally, Entropy Technologies LP raised its holdings in Royalty Pharma by 38.1% in the 3rd quarter. Entropy Technologies LP now owns 81,146 shares of the biopharmaceutical company’s stock valued at $4,736,000 after buying an additional 22,379 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.
About Royalty Pharma
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Recommended Stories
- Five stocks we like better than Royalty Pharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
